Medical devices, healthcare technology and the business of care
510(k) clearance · K250233

PreemptiveAI Clinical SDK

Measure Labs, Inc. (Dba Preemptiveai, Inc.) · Decision date Feb 13, 2026

FDA DECISIONK250233

What did the FDA decide?

FDA records K250233 as a 510(k) premarket notification, with a decision dated Feb 13, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Feb 13, 2026

FDA source record

Regulatory record facts

Identifier
K250233
Regulatory pathway
510(k) premarket notification
Product code
DXH
Decision code
SESE
Decision date
Feb 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Transmitters And Receivers, Electrocardiograph, Telephone.

Product code
DXH
FDA device class
2

FDA decision timeline

  1. K250233 received

    Application receipt date recorded by FDA.

  2. K250233 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Measure Labs, Inc. (Dba Preemptiveai, Inc.)

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Seattle, WA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records